Evaluating the Effect of Inositol Supplementation in Overweight Children on Basal Insulin and Body Weight
- Conditions
- Insulin Resistance
- Interventions
- Other: PlaceboDietary Supplement: Inofolic Combi
- Registration Number
- NCT03920787
- Lead Sponsor
- Alice Andreassi
- Brief Summary
Inositol in involved in the insulin pathway. In literature it has been demonstrated to improve insulin sensitivity and ovarian function in women affected by PCOS.
In a preliminary study conducted on obese children between 7 and 15 years, the investigators have demonstrated that Inositol administration (Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg) before a Glucose Oral Tolerance Test reduces the increase of insulin levels, particularly in subjects with basal insulin ≥ 15 uU/ml.
So the aim of this study is to evaluate the potential therapeutic effect of inositol, as non-pharmacologic agent, in preventing tipe II diabetes in children.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 23
- 8-18 years old
- overweight or obesity
- basal insulin ≥ 20 uU/ml
- pubertal delay
- hypogonadism
- hypothyroidism or hyperthyroidism
- obesity-related genetic diseases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo Placebo Administration of placebo. 2 capsules every day for 1 month Inositol Inofolic Combi Administration of Inofolic Combi (Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg - Lo.Li Pharma S.r.l.) 2 capsules every day for 1 month
- Primary Outcome Measures
Name Time Method Basal Insulin 1 month Evaluation of the efficacy of inositol in reducing basal insulin
- Secondary Outcome Measures
Name Time Method Body weight 1 month Evaluation of the efficacy of inositol in reducing body weight
Trial Locations
- Locations (1)
AO San Paolo
🇮🇹Milan, Mi, Italy